Experimental drug combo targets Hard-to-Treat pancreatic cancer
NCT ID NCT04158635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether adding the drug bosentan to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with pancreatic cancer that cannot be removed by surgery. The study involves 21 adults and aims to find the best dose of bosentan while monitoring side effects. Researchers hope this combination may slow or stop tumor growth better than chemotherapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bosentan (a drug that blocks the hormone endothelin) combined with chemotherapy drugs gemcitabine and nab-paclitaxel
- What this could lead to
- If it works, this could point toward a new combination treatment to help control advanced pancreatic cancer that cannot be surgically removed.
- What could go wrong
- This is a very early Phase 1 trial with only 21 participants, focused on safety and dosing. The study is currently suspended, and it is unknown if the combination will improve outcomes or cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III PANCREATIC CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
- Can a tailored web portal help pancreatic cancer patients exercise and eat better during chemotherapy?
- Home monitoring may keep cancer patients out of the ER
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- New drug cocktail targets tough pancreatic tumors